Summary & Overview
HCPCS J9215: Injection, Interferon Alfa-n3, 250,000 IU
HCPCS Level II code J9215 denotes the injection of interferon alfa-n3 (human leukocyte derived), 250,000 IU. This biologic injectable is used in therapeutic settings where interferon alfa-n3 is clinically indicated. Nationally, J9215 matters because it represents a specialty injectable medication with implications for drug acquisition, site-of-service selection, and payer coverage policy for biologic therapies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for interferon alfa-n3 administration, expected sites of service, and the service line classification. The publication provides benchmarks and payment context for the code, highlights relevant policy considerations affecting coverage and billing for injectable biologics, and summarizes common billing modifiers used with specialty drug injections.
The report addresses billing practices and reimbursement considerations at a national level, equips billing staff and administrators with code-specific information, and outlines where to find more detailed payer-specific guidance. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J9215 represents the injection of interferon alfa-n3 (human leukocyte derived), 250,000 IU. This code describes a biologic injectable medication administered to patients who require interferon alfa-n3 therapy.
Service Type: Injection / Therapeutic Drug Administration
Typical Site of Service: Outpatient clinic, physician office, or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving immunotherapy for a chronic viral infection or as adjunctive therapy where interferon alfa-n3 (human leukocyte derived) is indicated. The patient presents to an outpatient infusion clinic or physician office for a scheduled intramuscular or subcutaneous injection billed as J9215 (per 250,000 IU). The clinical workflow includes verification of indication and informed consent, review of prior doses and current labs (complete blood count, liver function tests, thyroid function as clinically indicated), medication preparation by pharmacy with appropriate lot documentation, and administration by a licensed nurse. Post-injection observation for immediate adverse reactions (15–30 minutes) is performed with documentation of dose, route, site, lot number, and patient's tolerance. Follow-up visits document response, tolerability, and any dose modifications or treatment discontinuation due to toxicity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no reporting modifier is applicable and service is unmodified. |
22 |